Court overturns $482M patent decision against J&J

(AP)—A federal appeals court says that a Johnson & Johnson heart stent does not infringe a patent held by a doctor and inventor, overturning a $482 million decision against the company.

The three-judge panel said a lower court misinterpreted the company's patent and should not have ruled in favor of Bruce Saffran, a doctor from Princeton, N.J.

Heart stents are mesh-wire tubes that prop open arteries affected by coronary artery disease. The dispute centered over drug-eluting stents, which release a drug to help keep arteries from clogging.

Saffran sued J&J in 2007 saying its Cypher stents infringed on his 1997 patent covering technology to deliver medication inside the body. A Texas jury ruled in Saffran's favor in 2011, concluding J&J had willfully infringed on his .

0 shares

Related Stories

Court Denies Vonage Bid for Patent Case Retrial

date May 04, 2007

A U.S. appeals court denies a request by Internet phone company Vonage Holdings that it order a retrial in the patent infringement case brought against it by Verizon Communications.

Off-label use of stents investigated

date Mar 07, 2007

A federal committee is investigating the off label use of drug-coated heart stents by U.S. doctors, The Wall Street Journal reported Tuesday.

Microsoft asks court to hold off on Word ban

date Aug 19, 2009

(AP) -- Microsoft Corp. is asking the U.S. Court of Appeals for the Federal Circuit to allow it to keep selling Word software as it fights an unfavorable patent ruling.

Recommended for you

ER doctors stress need for good communications with police

date May 26, 2015

A good working relationship with police is essential for the smooth operation of a busy Emergency Department. Police are in and out of EDs regularly, supporting EMS, transporting patients and helping to provide a safe environment ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.